colfosceril

colfosceril

 [kol-fos´ĕ-ril]
a synthetic pulmonary surfactant used as the palmitate ester in combination with tyloxapol and an alcohol in prophylaxis and treatment of neonatal respiratory distress syndrome; instilled into the endotracheal tube for intratracheal administration.
References in periodicals archive ?
In the study, the infants were treated with lucinactant (Surfaxin), colfosceril palmitate (Exosurf), or beractant (Survanta) within 30 minutes of birth.
In addition to colfosceril and beractant, the other two FDA-approved surfactants are poractant alpha (Curosurf) and calfactant (Infasurf).
One of the first available protein-free, artificial surfactant preparations was Exosurf, or colfosceril palmitate plus cetyl alcohol and tyloxapol.
Lucinactant Comparison Trial to Colfosceril palmitate and Beractant
In 2005, Moya et al published a large prospective randomized clinical trial that reported a higher RDS mortality rate for colfosceril palmitate (a synthetic surfactant) and beractant (a natural surfactant) than for lucinactant.
One third of the patients were in 2 cells (lucinactant >1,000 g and colfosceril >1,000 g).
Exosurf (colfosceril palmitate), which was the only synthetic surfactant on the market, has been removed.
It is a natural bovine lung extract mixed with colfosceril palmitate (DPPC), palmitic acid, and tripalmitin.